Press release
Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Amyotrophic Lateral Sclerosis Pipeline Drugs
Amyotrophic lateral sclerosis is the most common degenerative disease of the motor neuron system, enables destroy nerve cells and causes disability. Amyotrophic lateral sclerosis is known as Lou Gehring’s disease.
Amyotrophic lateral sclerosis often begins with muscle twitching and weakness in a limb, or slurred speech. Afterwards, may affects the control of the muscles involved in movement, speaking, eating and breathing. There is no cure for the disease and eventually disease is fatal.
The disease is inherited in 5% to 10% of cases and rest is unknown etiology. Researchers are studying several possible causes including gene mutation, chemical imbalance, and protein mishandling and disorganized immune response. Amyotrophic lateral sclerosis is difficult to diagnose, because it mimics various neurological disease symptoms. Generally ALS diagnosed using electromyogram, nerve conduction study, MRI, spinal tap and muscle biopsy. Blood and urine test are performed to sort out the other possible signs and symptoms.
Two FDA approved drugs are available in the market, namely Riluzole and endaravone. Various therapies are available to reduce the symptoms of the disease.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/amyotrophic-lateral-sclerosis-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
The pipeline drugs are segmented based on route of administration, trial phase, and company
By route of administration, amyotrophic lateral sclerosis pipeline drugs are segmented into
• Oral
• Parenteral
• Others
By trial phase, amyotrophic lateral sclerosis pipeline drugs are segmented into
• Pre-clinical phase
• Phase-I
• Phase II
• Phase-III
By company, amyotrophic lateral sclerosis pipeline drugs are segmented into
• Mallinckrodt Pharmaceuticals
• ASTELLAS PHARMA INC. (JAPAN)
• REVALESIO CORPORATION (U.S.)
• Amylyx Pharmaceutical Corp. (U.S.)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• AB Science (France)
• H. Boehringer Sohn AG &Co. KG (Germany)
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/amyotrophic-lateral-sclerosis-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
Most of the pipeline drugs for treatment of amyotrophic lateral sclerosis pipeline are at preclinical stages. Companies with pipeline molecules mostly focused on neuro protection, immunomodulation, and glutamate excitotoxicity blockers for the treatment of amyotrophic lateral sclerosis.
• In November 2017, U.S. Food and Drug Administration has given clearance of the clinical investigation of Biohaven Pharmaceutical’s sublingual lead, BHV-0223 for the treatment of amyotrophic lateral sclerosis.
• In September 2017, U.S. Food and Drug Administration granted orphan drug designation to Revalesio’s investigational drug RNS60 to treat Amyotrophic Lateral Sclerosis (ALS).
Report Description:
Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugs development. This report studies the dynamics of the Amyotrophic Lateral Sclerosis Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/amyotrophic-lateral-sclerosis-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis of each drug candidates in the clinical trial phases
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/amyotrophic-lateral-sclerosis-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here
News-ID: 1049141 • Views: …
More Releases from Precision Business Insights
Biochar Market Growth Is Attributed To The Increased Production Of Biochar Throu …
According to Precision Business Insights (PBI), the latest report biochar market was valued at USD 243.8 million in 2022, growing at a 12.6% CAGR during the forecast period 2023 to 2029. The rising demand for organic and eco-friendly products drives the biochar market. Utilizing biochar corresponds with organic farming methods, improving market prospects. Furthermore, biochar is a potential material for water treatment and remediation because of its capacity to absorb…
Vapor Recovery Units Market Growth Is Attributed To The Increased Adoption Of Me …
According to Precision Business Insights (PBI), latest report vapor recovery units market was valued at USD 923.7 million in 2022 and is poised to grow at a CAGR of 4.2% during the forecast period 2023 to 2029. The adoption of stringent environmental regulations by governments and international bodies to reduce air pollution and greenhouse gas emissions in various countries drives the demand for the vapor recovery unit's market. Furthermore, the…
Pyrite Market Growth Is Attributed To The Increased Demand In Jewelry Industry
According to Precision Business Insights (PBI), latest report pyrite market is growing at 4.9% CAGR during the forecast period 2023 to 2029. The increased application of pyrite in the manufacturing of sulfuric acid drives the pyrite market. The increase of prices of gold has led to increased demand for imitation jewelry which is anticipated to propel the pyrite market growth. Furthermore, the demand for sulphuric acid in a variety of…
Industrial Boilers Market Growth Is Attributed To The Increased Use In Power Gen …
According to Precision Business Insights (PBI), the latest report industrial boilers market size was valued at USD 15,261.8 million in 2022 and is poised to grow at a 3.1% CAGR during the forecast period 2023 to 2029. The adoption of stringent environmental regulations to maintain emission standards and carbon reduction in several countries drives the industrial boilers market. Furthermore, the advancement in boiler technology, such as better combustion systems, greater…
More Releases for Amyotrophic
Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
The global market for amyotrophic lateral sclerosis devices or motor neuron disease devices anticipated to reach $19.5 billion by 2029, growing at a CAGR of 7.3% over the forecast period, driven by increasing incidence, rising geriatric population, lack of curative treatment, growing public awareness, and technological advancements in palliative care.
https://www.ihealthcareanalyst.com/global-amyotrophic-lateral-sclerosis-devices-market/
Amyotrophic lateral sclerosis or Lou Gehrig's disease or motor neuron disease (MND) is characterized by progressive degeneration of the motor nerve…
Amyotrophic Lateral Sclerosis Treatment Market Report Up to 2031
Visiongain has published a new report on Amyotrophic Lateral Sclerosis Treatment Market Report to 2031: Forecasts by Treatment Type (Chemotherapy and Stem Cell Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS COVID-19 Recovery Scenarios.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/als-treatment-market/#download_sampe_div
COVID-19 Impact on Amyotrophic Lateral Sclerosis Treatment Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the Amyotrophic Lateral Sclerosis Treatment market is anticipated…
Amyotrophic Lateral Sclerosis Treatment Market Growth and Opportunity Analysis
Allied Market Research published a report, titled, “Amyotrophic Lateral Sclerosis Treatment Market: Global Opportunity Analysis and Industry Forecast 2019–2026.” According to the report, the global Amyotrophic Lateral Sclerosis Treatment industry garnered $XX billion in 2019, and is expected to generate $xx billion by 2027, witnessing a CAGR of xx% from 2020 to 2027.
Click Here To Access Sample Report https://www.alliedmarketresearch.com/request-sample/10609
Major players analyzed include Sun Pharmaceutical, Mitsubishi Tanabe Pharma America, Biogen,…
Global Amyotrophic Lateral Sclerosis Market Research Report - Forecast to 2023
Amyotrophic Lateral Sclerosis Market 2020 comprises a detailed survey of the Amyotrophic Lateral Sclerosis Market size, share, trends, extension, consumption, and share, segments, application and Forecast 2025.
Global "Amyotrophic Lateral Sclerosis" Market 2020-2025 Report contains all demographic as well as analytical data regarding market review, growth, demand, and budget analysis. The report mainly highlights the significant trends of the Amyotrophic Lateral Sclerosis market in terms of thriving companies, business methods, product…
Amyotrophic Lateral Sclerosis (ALS) Treatment Market : Trends And Growth
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time.
According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate…
Amyotrophic Lateral Sclerosis Market to increase rapidly by 2024
Amyotrophic lateral sclerosis (ALS) is a neurological disease and also termed as Lou Gehrig’s disease. The disease affects the motor neurons, which control the action of voluntary muscles, as a result the messages between brain and muscle fibers are blocked. ALS could occur in a person due to genetic inheritance, mutation in gene which encodes enzyme copper-zinc superoxide dismutase coupled with defect in chromosome 9. This disease is more prevalent…
